EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the Effects of Baricitinib in Patients with Acute Respiratory Distress Syndrome: A Pilot, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Mehdi Nurmohammad Ahari, Shadi Ziaie, Ata Mahmoodpoor, Hassan Soleimanpour, Hamed Valizadeh, Fariba Pourkarim, Saman Chaparzadeh, Hadi Hamishehkar

Pharmaceutical Sciences · 31.10.2026 · 32 (4) · 640-646

DOI: 10.34172/ps.43120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 29.03.2026. Verfasst von Mehdi Nurmohammad Ahari und 7 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite advances in supportive care, acute respiratory distress syndrome (ARDS) remains a major cause of mortality and morbidity in critically ill patients. The lack of effective pharmacological treatments underscores the necessity for novel, evidence-based therapies. Investigating baricitinib’s potential to improve outcomes could address unmet needs and transform management strategies in this serious condition.

Methods

This double-blind, placebo-controlled clinical trial enrolled 20 patients with ARDS at Imam Reza Hospital, Tabriz. Participants were randomly assigned to two groups and received either baricitinib or a placebo. All patients received standard supportive care throughout hospitalization. Demographic and clinical data were collected from medical records and bedside interviews. Outcomes were assessed over 28 and 60 days, with both clinical and laboratory markers.

Results

Intervention group showed a greater improvement in the arterial oxygenation (PaO₂/FiO₂ ratio) versus the placebo group but there was no significant difference between the two groups from the baseline through day 14 (P=0.37). Significant difference was observed in the reduced need for advanced respiratory support (P

Zitieren

APA

Ahari, M. N., Ziaie, S., Mahmoodpoor, A., Soleimanpour, H., Valizadeh, H., Pourkarim, F., Chaparzadeh, S., & Hamishehkar, H. (2026). Evaluation of the Effects of Baricitinib in Patients with Acute Respiratory Distress Syndrome: A Pilot, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pharmaceutical Sciences, 32(4), 640-646. https://doi.org/10.34172/ps.43120

Vancouver

Ahari MN, Ziaie S, Mahmoodpoor A, Soleimanpour H, Valizadeh H, Pourkarim F, et al. Evaluation of the Effects of Baricitinib in Patients with Acute Respiratory Distress Syndrome: A Pilot, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Pharmaceutical Sciences. 2026;32(4):640-646. doi:10.34172/ps.43120

BibTeX
@article{Ahari2026,
  author = {Ahari, Mehdi Nurmohammad and Ziaie, Shadi and Mahmoodpoor, Ata and Soleimanpour, Hassan and Valizadeh, Hamed and Pourkarim, Fariba and Chaparzadeh, Saman and Hamishehkar, Hadi},
  title = {Evaluation of the Effects of Baricitinib in Patients with Acute Respiratory Distress Syndrome: A Pilot, Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
  journal = {Pharmaceutical Sciences},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {640--646},
  doi = {10.34172/ps.43120}
}
Kostenlos starten →